Want to see IMRX full AI Analyst Report?
Total Valuation
Immuneering has a market cap or net worth of $327.37M. The enterprise value is $176.57.
Market Cap$327.37M
Enterprise Value$176.57
Share Statistics
Immuneering has 64,697,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,697,400
Owned by Insiders9.38%
Owned by Institutions9.33%
Financial Efficiency
Immuneering’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.71%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-26.71%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-1.02M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immuneering is ―. Immuneering’s PEG ratio is 0.14.
PE Ratio―
PS Ratio0.00
PB Ratio1.33
Price to Fair Value1.33
Price to FCF-6.37
Price to Operating Cash Flow>-0.01
PEG Ratio0.14
Income Statement
In the last 12 months, Immuneering had revenue of 0.00 and earned -56.02M in profits. Earnings per share was -1.27.
Revenue0.00
Gross Profit-698.89K
Operating Income-59.38M
Pretax Income-56.02M
Net Income-56.02M
EBITDA-55.33M
Earnings Per Share (EPS)-1.27
Cash Flow
In the last 12 months, operating cash flow was -34.96B and capital expenditures -107.43M, giving a free cash flow of -35.06B billion.
Operating Cash Flow-34.96B
Free Cash Flow-35.06B
Free Cash Flow per Share-541.97
Dividends & Yields
Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.99
52-Week Price Change44.57%
50-Day Moving Average4.60
200-Day Moving Average5.37
Relative Strength Index (RSI)61.47
Average Volume (3m)1.27M
Important Dates
Immuneering upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 5, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Immuneering as a current ratio of 17.50, with Debt / Equity ratio of 1.91%
Current Ratio17.50
Quick Ratio17.50
Debt to Market Cap0.00
Net Debt to EBITDA2.26
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immuneering has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immuneering EV to EBITDA ratio is -2.98, with an EV/FCF ratio of -3.62.
EV to Sales0.00
EV to EBITDA-2.98
EV to Free Cash Flow-3.62
EV to Operating Cash Flow-3.63
Balance Sheet
Immuneering has $149.90M in cash and marketable securities with $3.63M in debt, giving a net cash position of $146.27M billion.
Cash & Marketable Securities$149.90M
Total Debt$3.63M
Net Cash$146.27M
Net Cash Per Share$2.26
Tangible Book Value Per Share$4.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immuneering is $16.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.20
Price Target Upside275.00% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast45.56%